<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" dtd-version="1.3" xml:lang="EN" article-type="rapid-communication"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">ACS Med Chem Lett</journal-id><journal-id journal-id-type="iso-abbrev">ACS Med Chem Lett</journal-id><journal-id journal-id-type="publisher-id">ml</journal-id><journal-id journal-id-type="coden">amclct</journal-id><journal-title-group><journal-title>ACS Medicinal Chemistry Letters</journal-title></journal-title-group><issn pub-type="epub">1948-5875</issn><publisher><publisher-name>American Chemical Society</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC10726465</article-id><article-id pub-id-type="doi">10.1021/acsmedchemlett.3c00426</article-id><article-categories><subj-group><subject>Letter</subject></subj-group></article-categories><title-group><article-title>Synthesis
and Evaluation of Small Molecule Inhibitors
of the Androgen Receptor N-Terminal Domain</article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><name><surname>Henry</surname><given-names>Martyn
C.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="notes3" ref-type="notes">&#x02225;</xref></contrib><contrib contrib-type="author" id="ath2"><name><surname>Riley</surname><given-names>Christopher M.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="notes3" ref-type="notes">&#x02225;</xref></contrib><contrib contrib-type="author" id="ath3"><name><surname>Hunter</surname><given-names>Irene</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath4"><name><surname>Elwood</surname><given-names>Jessica M. L.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath5"><name><surname>Lopez-Fernandez</surname><given-names>J. Daniel</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath6"><name><surname>Minty</surname><given-names>Laura</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath7"><name><surname>Coe</surname><given-names>Diane M.</given-names></name><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath8"><name><surname>McEwan</surname><given-names>Iain J.</given-names></name><xref rid="cor2" ref-type="other">*</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath9"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6567-8272</contrib-id><name><surname>Jamieson</surname><given-names>Craig</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><aff id="aff1"><label>&#x02020;</label>Department
of Pure and Applied Chemistry, <institution>University
of Strathclyde</institution>, 295 Cathedral Street, Glasgow G1 1XL, <country>U.K.</country></aff><aff id="aff2"><label>&#x02021;</label>Institute
of Medical Sciences, <institution>University of Aberdeen</institution>, Foresterhill, Aberdeen AB25 2ZD, <country>U.K.</country></aff><aff id="aff3"><label>&#x000a7;</label>Medicine
Design, <institution>GlaxoSmithKline R&#x00026;D Ltd</institution>, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, <country>U.K.</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Email: <email>craig.jamieson@strath.ac.uk</email>.</corresp><corresp id="cor2"><label>*</label>Email: <email>iain.mcewan@abdn.ac.uk</email>.</corresp></author-notes><pub-date pub-type="epub"><day>17</day><month>11</month><year>2023</year></pub-date><pub-date pub-type="collection"><day>14</day><month>12</month><year>2023</year></pub-date><pub-date pub-type="pmc-release"><day>17</day><month>11</month><year>2023</year></pub-date><volume>14</volume><issue>12</issue><fpage>1800</fpage><lpage>1806</lpage><history><date date-type="received"><day>20</day><month>09</month><year>2023</year></date><date date-type="accepted"><day>13</day><month>11</month><year>2023</year></date><date date-type="rev-recd"><day>10</day><month>11</month><year>2023</year></date></history><permissions><copyright-statement>&#x000a9; 2023 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>The Authors</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml3c00426_0012" id="ab-tgr1"/></p><p>The androgen receptor (AR) is central to prostate cancer
pathogenesis
and has been extensively validated as a drug target. However, small-molecule
anti-androgen therapies remain limited due to resistance and will
eventually fail to suppress tumor growth, resulting in progression
to castration-resistant prostate cancer (CRPC). The intrinsically
disordered N-terminal domain (NTD) is crucial for AR transactivation
and has been investigated as a suitable target in the presence of
ligand binding domain mutations. A screening campaign identified biaryl
isoxazole compound <bold>7</bold> as a weak inhibitor of the AR NTD.
A library of biaryl analogues were synthesized, and their biological
activities were assessed in a VCaP cell-based luciferase reporter
gene assay. A structure&#x02013;activity relationship (SAR) study revealed
that indazole analogue <bold>16</bold> exhibited increased potency
and favorable physicochemical properties with a benchmarked pharmacokinetic
profile, providing a suitable starting point for further optimization
of <bold>16</bold> as a CRPC therapeutic in the presence of AR mutations.</p></abstract><kwd-group><kwd>Prostate cancer</kwd><kwd>Androgen receptor</kwd><kwd>Intrinsically
disordered protein</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution>GlaxoSmithKline</institution><institution-id institution-id-type="doi">10.13039/100004330</institution-id></institution-wrap></funding-source><award-id>NA</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>Prostate Cancer Research</institution><institution-id institution-id-type="doi">NA</institution-id></institution-wrap></funding-source><award-id>NA</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>Medical Research Council</institution><institution-id institution-id-type="doi">10.13039/501100000265</institution-id></institution-wrap></funding-source><award-id>MR/T02559/X</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>ml3c00426</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>ml3c00426</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><p>Prostate cancer remains the
second most common cancer, with one in eight men receiving a diagnosis
in their lifetime and almost 400,000 deaths worldwide in 2020 alone.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> Despite significant advances in localized prostate
cancer therapies, around 20&#x02013;30% of patients will subsequently
present with advanced and metastatic forms of the disease and will
require systemic treatment.<sup><xref ref-type="bibr" rid="ref2">2</xref>&#x02212;<xref ref-type="bibr" rid="ref4">4</xref></sup> While effective at inducing remission
and offering a relief from symptoms, treatments such as androgen deprivation
therapy (ADT) ultimately only slow the course of the disease before
almost inevitable progression to castration-resistant prostate cancer
(CRPC), which is associated with a poor prognosis.<sup><xref ref-type="bibr" rid="ref5">5</xref>,<xref ref-type="bibr" rid="ref6">6</xref></sup> Central
to prostate cancer pathogenesis is the nuclear androgen receptor (AR),
a 110 kDa transcription factor which is primarily responsible for
androgen-mediated regulation of gene expression.<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> In common with all nuclear receptors, the AR protein consists
of the ligand-binding domain (LBD), in which the ligand binding pocket
(LBP) is located; the DNA-binding domain (DBD); the N-terminal domain
(NTD); and a hinge region which connects the LBD with the DBD. Due
to the critical role of the AR protein in the progression of prostate
cancer, AR antagonists that compete with androgens for binding in
the LBP are used clinically and have traditionally been the primary
focus of drug discovery campaigns.<sup><xref ref-type="bibr" rid="ref8">8</xref>&#x02212;<xref ref-type="bibr" rid="ref10">10</xref></sup> In this regard, the
second-generation nonsteroidal anti-androgens (NSAAs) enzalutamide
(<bold>1</bold>), apalutamide (<bold>2</bold>), and darolutamide (<bold>3</bold>) have all been approved within the past decade for the treatment
of CRPC (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>).<sup><xref ref-type="bibr" rid="ref11">11</xref>&#x02212;<xref ref-type="bibr" rid="ref13">13</xref></sup> However, anti-androgen therapies will eventually fail to suppress
tumor growth due to a complex array of resistance mechanisms, which
inevitably leads to reactivation of the AR signaling axis.<sup><xref ref-type="bibr" rid="ref14">14</xref>&#x02212;<xref ref-type="bibr" rid="ref19">19</xref></sup> For this reason, alternative small-molecule CRPC therapies have
been sought that do not rely on binding to the canonical LBD but instead
target other domains of the AR.<sup><xref ref-type="bibr" rid="ref20">20</xref>&#x02212;<xref ref-type="bibr" rid="ref22">22</xref></sup> It has been shown that the NTD
is critical for the transactivation and function of AR, in which the
modular activation function (AF-1) is of particular importance for
gene expression and in facilitating protein&#x02013;protein interactions.<sup><xref ref-type="bibr" rid="ref23">23</xref>,<xref ref-type="bibr" rid="ref24">24</xref></sup> However, due to the intrinsically disordered nature of this domain,
it is not amenable to structure-based drug design and has therefore
garnered less attention as a potential target for therapeutic intervention
in the past.<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> Despite this, in the past
decade, several small molecules have been developed which act on the
AR via the disordered NTD.<sup><xref ref-type="bibr" rid="ref26">26</xref>&#x02212;<xref ref-type="bibr" rid="ref35">35</xref></sup> For example, the EPI family of compounds,<sup><xref ref-type="bibr" rid="ref36">36</xref>&#x02212;<xref ref-type="bibr" rid="ref39">39</xref></sup> including racemic EPI-001 (<bold>4</bold>), have been reported to block AR transcription via interaction
with the AF-1 region of the AR-NTD, while other EPI analogues (EPI-002
(<bold>5</bold>) and EPI-7170 (<bold>6</bold>)) have been shown to
induce conformation changes within the NTD and disrupt interactions
between the AF1 and essential protein coactivators.<sup><xref ref-type="bibr" rid="ref40">40</xref></sup> Furthermore, EPI-7386 (structure not disclosed) is currently
in phase-1 clinical trials and has effectively demonstrated that AR
NTD inhibitors could be potential therapeutics in the presence of
LBD-driven resistance in the context of CPRC.<sup><xref ref-type="bibr" rid="ref41">41</xref>,<xref ref-type="bibr" rid="ref42">42</xref></sup></p><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Clinically
relevant nonsteroidal AR antagonists and recent AR-NTD
AF1 binders.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml3c00426_0001" id="gr1" position="float"/></fig><p>Herein we report our work toward the design, synthesis,
and biological
evaluation of a novel series of biaryl small-molecule antagonists
of the AR receptor NTD. Previous work within our laboratories identified
compound <bold>7</bold> as a weak binder of AR splice variants (AR-vs)
lacking the LBD using a high-throughput screen utilizing a functional
cell-based assay developed in our group, with hits from this assay
counterscreened for cytoxicity and inhibition of luciferase activity
to confirm specific activity.<sup><xref ref-type="bibr" rid="ref43">43</xref></sup> In an effort
to develop understanding of the structure&#x02013;activity relationship
(SAR) and identify more potent AR-NTD inhibitor analogues, we synthesized
analogues of <bold>7</bold> focusing largely on changes to the LHS
heterocyclic region, alternative substituents on the RHS aromatic
ring, and replacement of the potentially metabolically labile thioether
functional group (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>a).</p><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Proposed structural modifications and synthesis of initial HTS
hit compound <bold>7</bold>. Reagents and conditions: (a) NaNO<sub>2</sub>, 1 M HCl, rt, 1 h, then NaSMe, rt, 2 h, 86%; (b) 4 M NaOH,
THF/EtOH (1:1), rt, 16 h, quant.; (c) (COCl)<sub>2</sub>, DMF, THF,
rt, 1 h, then NH<sub>4</sub>OH, 0 &#x000b0;C, 2 h, 74%; (d) ethyl vinyl
ether, Pd(dppf)Cl<sub>2</sub>&#x000b7;CH<sub>2</sub>Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, DMF/H<sub>2</sub>O (9:1), 90 &#x000b0;C, 64 h,
then 2 M HCl, rt, 0.5 h, 43%; (e) NaH, EtOCHO, rt, 24 h; (f) H<sub>2</sub>NOH&#x000b7;HCl, EtOH, 85 &#x000b0;C, 1 h, 25% over two steps.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml3c00426_0002" id="gr2" position="float"/></fig><p>Our current work began with the validation of our
screening-derived
hit compound <bold>7</bold> in a cell-based reporter gene assay. This
required the synthesis of compound <bold>7</bold> from readily available
starting materials, which is shown in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>b. Aniline <bold>7a</bold> was converted
to the corresponding diazonium salt by treatment with sodium nitrite,
which was followed by a Sandmeyer-type reaction with sodium methanethiolate
that provided thioether <bold>7b</bold> in 86% yield. Hydrolysis of
the ester group followed by amidation via <italic>in situ</italic> formation of the Vilsmier reagent afforded primary carboxamide <bold>7d</bold>. Palladium-catalyzed Heck reaction with ethyl vinyl ether
gave the intermediate enol ether, which was hydrolyzed under acidic
conditions to afford ketone <bold>7e</bold> in 43% yield. Finally,
formylation of the &#x003b1;-position of the carbonyl in the presence
of sodium hydride followed by ring closure with hydroxylamine afforded
isoxazole <bold>7</bold> in 25% yield over two steps. Compound <bold>7</bold> was then evaluated in our VCaP cell-based GRE2-luciferase
reporter gene assay and was found to have an IC<sub>50</sub> of 7.4
&#x003bc;M.</p><p>For reference, the benchmark AR antagonist enzalutamide
(<bold>1</bold>) and EPI-001 (<bold>4</bold>) were also examined for
their
effect against GRE2-luciferase activity in our hands (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>). In this assay, enzalutamide
was very potent, with an IC<sub>50</sub> of 0.34 &#x003bc;M, while EPI-001
had an IC<sub>50</sub> of 37.4 &#x003bc;M.</p><p>As shown in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>a, the four main
regions of the template were targeted for further
SAR study. In our initial investigations into modifications of the
LHS region, the biaryl C&#x02013;C bond was used as a linchpin disconnection,
with alternative heterocyclic groups being introduced via Suzuki&#x02013;Miyaura
cross-coupling with aryl bromide <bold>7d</bold> and a range of boronic
acids under thermal or microwave conditions (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>; see the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.3c00426/suppl_file/ml3c00426_si_001.pdf">Supporting Information</ext-link> for further details). Compound <bold>8</bold> with
an unfunctionalized phenyl ring was inactive in our assay.</p><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><title>Region 1 Investigations into Alternative
RHS Heterocyclic Scaffolds<xref rid="tbl1-fn1" ref-type="table-fn">a</xref></title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml3c00426_0004" id="GRAPHIC-d14e424-autogenerated" position="float"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml3c00426_0005" id="GRAPHIC-d14e425-autogenerated" position="float"/><table-wrap-foot><fn id="tbl1-fn1"><label>a</label><p>Conditions: (A) XPhos-Pd-G2 (5
mol %), K<sub>3</sub>PO<sub>4</sub>, toluene/water (9:1), 90 &#x000b0;C,
16 h; (B) Pd(PPh<sub>3</sub>)<sub>4</sub> (10 mol %), K<sub>3</sub>PO<sub>4</sub>, DMF/water (9:1), 90 &#x000b0;C, 16 h; (C) Pd(PPh<sub>3</sub>)<sub>4</sub> (7.5 mol %), Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/water
(9:1), 120 &#x000b0;C, 20 min (see the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.3c00426/suppl_file/ml3c00426_si_001.pdf">Supporting Information</ext-link>).</p></fn></table-wrap-foot></table-wrap><p>Following this, the LHS region was explored via the
introduction
of smaller, five-membered heterocyclic motifs. Thiophene <bold>9</bold> showed robust activity (IC<sub>50</sub> = 0.60 &#x003bc;M), while
dimethylisooxazole <bold>10</bold> was weakly active (IC<sub>50</sub> = 4.7 &#x003bc;M) and pyrrole <bold>11</bold> retained no activity.
Next, benzannulated heterocycles bearing hydrogen-bond donors (HBDs)
were examined. Indazole <bold>12</bold> showed good activity, with
an IC<sub>50</sub> of 0.70 &#x003bc;M, while indole <bold>13</bold> displayed
a 10-fold decrease in activity (IC<sub>50</sub> = 10.3 &#x003bc;M).
Interestingly, indazole <bold>14</bold> featuring different connectivity
compared with analogue <bold>12</bold>, such that the HBD is oriented
in a different direction, was less potent (IC<sub>50</sub> = 2.2 &#x003bc;M).
Activity was recovered with imidazole <bold>15</bold>, which displayed
an IC<sub>50</sub> of 0.92 &#x003bc;M. Removing the HBD from the RHS
heterocycle by blocking the free NH group of indazole <bold>12</bold> with a methyl substituent gave compound <bold>16</bold>, which exhibited
excellent potency (IC<sub>50</sub> = 0.12 &#x003bc;M). This represents
a 60-fold increase in potency over our initial hit compound <bold>7</bold> and compares favorably with enzalutamide (IC<sub>50</sub> = 0.34 &#x003bc;M). Deletion of a nitrogen atom resulted in approximately
similar potency in <italic>N</italic>-methylindole <bold>17</bold> (IC<sub>50</sub> = 0.09 &#x003bc;M). Imidazopyridine <bold>18</bold> and oxoindole <bold>19</bold> were tested; however, both displayed
no activity. Quinoline <bold>20</bold> and isoquinoline <bold>21</bold> were active, both with an IC<sub>50</sub> of 0.80 &#x003bc;M, demonstrating
that the position of the nitrogen atom has no effect on the activity.
However, deleting the aryl ring resulted in a loss of activity of
pyridine analogues <bold>22</bold> and <bold>23</bold>. The addition
of a nitrogen atom in pyrimidine analogue <bold>24</bold> resulted
in recovery of activity with an IC<sub>50</sub> of 0.27 &#x003bc;M.
Our attention next focused on more lipophilic benzannulated heterocycles
such as benzo[<italic>b</italic>]furan <bold>25</bold>, benzoxazole <bold>26</bold>, and 2,3-dihydrobenzofuran <bold>27</bold>. Of these compounds,
only unsaturated benzo[<italic>b</italic>]furan <bold>25</bold> displayed
activity (IC<sub>50</sub> = 0.60 &#x003bc;M). Activity was abolished
in electron-rich acyclic ether analogue <bold>28</bold> but recovered
to an extent with the incorporation of a fluorine atom in analogue <bold>29</bold> (IC<sub>50</sub> = 0.76 &#x003bc;M). Increasing the electron
density of the ring and increasing the number of HBDs via the replacement
of a methoxy group with an aryl amine resulted in loss of activity
in compound <bold>30</bold>. We next examined fluorinated phenol isomers <bold>31</bold>, <bold>32</bold>, and <bold>33</bold>. Interestingly, the
position of the fluorine atom on the aromatic ring significantly influenced
the bioactivity, as <italic>ortho</italic> and <italic>meta</italic> analogues <bold>31</bold> and <bold>32</bold> were inactive while <italic>para</italic> derivative <bold>33</bold> was potent (IC<sub>50</sub> = 0.12 &#x003bc;M).</p><p>Subsequently, in an effort to improve solubility
and other physicochemical
properties, a &#x003c0;-deficient pyridine ring was introduced into
our scaffold in analogues <bold>34</bold>&#x02013;<bold>37</bold> (<xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>). It is clear from
matched molecular pairs <bold>34</bold> and <bold>16</bold> that the
pyridine ring is not tolerated on the RHS, resulting in a loss of
activity, perhaps due to unfavorable conformation changes or a decrease
in electron density. Substitution of a hydrogen atom for a fluorine
atom at the <italic>ortho</italic> position with respect to the thioether
in compound <bold>38</bold> gave activity (IC<sub>50</sub> = 0.24
&#x003bc;M) similar to that of compound <bold>16</bold>. Moving the
thioether group around the ring to furnish <italic>meta</italic> substitution
relative to the biaryl C&#x02013;C bond resulted in an inactive compound
(<bold>39</bold>).</p><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><title>Region 2 Investigations into Alternative
Substitutions of the LHS Aromatic Ring</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml3c00426_0006" id="GRAPHIC-d14e600-autogenerated" position="float"/><table frame="hsides" rules="groups" border="0"><colgroup><col align="char" char="."/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center" char=".">compound</th><th style="border:none;" align="center">substitution</th><th style="border:none;" align="center">IC<sub>50</sub> (&#x003bc;M)</th></tr></thead><tbody><tr><td style="border:none;" align="char" char="."><bold>34</bold></td><td style="border:none;" align="left">R&#x000a0;=&#x000a0;SMe,&#x000a0;X&#x000a0;=&#x000a0;N</td><td style="border:none;" align="left">&#x0003e;30</td></tr><tr><td style="border:none;" align="char" char="."><bold>35</bold></td><td style="border:none;" align="left">R&#x000a0;=&#x000a0;SBn,&#x000a0;X&#x000a0;=&#x000a0;N</td><td style="border:none;" align="left">&#x0003e;30</td></tr><tr><td style="border:none;" align="char" char="."><bold>36</bold></td><td style="border:none;" align="left">R&#x000a0;=&#x000a0;H,&#x000a0;X&#x000a0;=&#x000a0;N</td><td style="border:none;" align="left">&#x0003e;30</td></tr><tr><td style="border:none;" align="char" char="."><bold>37</bold></td><td style="border:none;" align="left">R&#x000a0;=&#x000a0;OMe,&#x000a0;X&#x000a0;=&#x000a0;N</td><td style="border:none;" align="left">&#x0003e;30</td></tr><tr><td style="border:none;" align="char" char="."><bold>38</bold></td><td style="border:none;" align="left">R&#x000a0;=&#x000a0;SMe,&#x000a0;X&#x000a0;=&#x000a0;CF</td><td style="border:none;" align="left">0.24</td></tr><tr><td style="border:none;" align="char" char="."><bold>39</bold></td><td style="border:none;" align="left">R&#x000a0;=&#x000a0;H,&#x000a0;X&#x000a0;=&#x000a0;C&#x02013;SMe</td><td style="border:none;" align="left">&#x0003e;30</td></tr></tbody></table></table-wrap><p>Replacement of the methyl thioether functionality
was next investigated,
as it was reasoned that this could be a potential metabolic liability
(<xref rid="tbl3" ref-type="other">Table <xref rid="tbl3" ref-type="other">3</xref></xref>). This required <italic>de novo</italic> synthesis from prefunctionalized starting materials
(see the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.3c00426/suppl_file/ml3c00426_si_001.pdf">Supporting Information</ext-link> for experimental
details). For example, ether starting materials were prepared by O-alkylation,
while nitrogen functionality was introduced via nucleophilic aromatic
substitution with the desired amine. Compounds <bold>40</bold>&#x02013;<bold>57</bold> were then delivered by subjecting these starting materials
to a palladium-catalyzed Suzuki&#x02013;Miyaura cross-coupling with
methylindazole boronic acid, as detailed previously.</p><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><title>Region 3 Investigations into Potential
Replacement of the Thioether Functional Group</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml3c00426_0007" id="GRAPHIC-d14e673-autogenerated" position="float"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml3c00426_0008" id="GRAPHIC-d14e674-autogenerated" position="float"/></table-wrap><p>First, replacement of the methyl group with a bulkier,
more lipophilic
benzyl group resulted in moderately potent compound <bold>40</bold> (IC<sub>50</sub> = 2.2 &#x003bc;M), while substitution of the thioether
with alkyl functionality (methyl <bold>41</bold> and ethyl <bold>42</bold>) resulted in loss of activity. Similarly, no bioactivity was observed
for compound <bold>43</bold> after removal of the thioether and replacement
with a hydrogen atom. While fluorinated analogue <bold>44</bold> was
inactive, compound <bold>45</bold> bearing a trifluoromethyl group
was weakly active, with an IC<sub>50</sub> of 8.6 &#x003bc;M. Attempts
to introduce ether functionality resulted in complete loss of activity,
with methyl ether <bold>46</bold>, benzyl ether <bold>47</bold>, and
trifluoromethyl ether <bold>48</bold> all displaying IC<sub>50</sub> &#x0003e; 30 &#x003bc;M. Furthermore, a similar lack of activity was observed
with free phenol derivative <bold>49</bold>, while bulkier ether analogues <bold>50</bold> and <bold>51</bold> were all inactive in our assay. Changing
the C&#x02013;O linkage to a C&#x02013;N bond in compound <bold>52</bold> resulted in modest activity, with an IC<sub>50</sub> of 0.94 &#x003bc;M.
Alternative N-linked analogues were synthesized, including cyclic
morpholine compound <bold>53</bold> and acyclic derivatives <bold>54</bold>&#x02013;<bold>57</bold>. Only analogue <bold>56</bold> featuring
a morpholine ring attached to the LHS aryl ring via a linear propyl
amine chain was active in the assay, with an IC<sub>50</sub> of 0.80
&#x003bc;M.</p><p>For reasons of synthetic tractability, molecular matched
pairs
of pyrimidine analogue <bold>24</bold> were investigated where the
primary carboxamide was replaced with tertiary amides via coupling
of carboxylic acid <bold>58</bold> with cyclic secondary amines (<xref rid="tbl4" ref-type="other">Table <xref rid="tbl4" ref-type="other">4</xref></xref>). In the VCaP GRE2-luciferase
assay, carboxylic acid <bold>58</bold> was active, with an IC<sub>50</sub> value of 0.12 &#x003bc;M, while tertiary amides <bold>59</bold> and <bold>60</bold> exhibited IC<sub>50</sub> values of 0.13 and
0.26 &#x003bc;M, respectively. Compounds <bold>59</bold> and <bold>60</bold> displayed comparable potency to matched pair <bold>24</bold>, which
suggests that the HBD capabilities of the primary amide are not crucial
for binding to the AR.</p><table-wrap id="tbl4" position="float"><label>Table 4</label><caption><title>Region 4 Investigations into Potential
Replacement of the Primary Carboxamide</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml3c00426_0009" id="GRAPHIC-d14e755-autogenerated" position="float"/><table frame="hsides" rules="groups" border="0"><colgroup><col align="char" char="."/><col align="left"/><col align="char" char="."/></colgroup><thead><tr><th style="border:none;" align="center" char=".">compound</th><th style="border:none;" align="center">substitution</th><th style="border:none;" align="center" char=".">IC<sub>50</sub> (&#x003bc;M)</th></tr></thead><tbody><tr><td style="border:none;" align="char" char="."><bold>58</bold></td><td style="border:none;" align="left">CO<sub>2</sub>H</td><td style="border:none;" align="char" char=".">0.12</td></tr><tr><td style="border:none;" align="char" char="."><bold>59</bold></td><td style="border:none;" align="left">X&#x000a0;=&#x000a0;CH<sub>2</sub></td><td style="border:none;" align="char" char=".">0.13</td></tr><tr><td style="border:none;" align="char" char="."><bold>60</bold></td><td style="border:none;" align="left">X&#x000a0;=&#x000a0;O</td><td style="border:none;" align="char" char=".">0.26</td></tr></tbody></table></table-wrap><p>During the SAR investigation of the core scaffold,
control of lipophilicity
was maintained with the aim of keeping this parameter in the desired
Lipinski-type space. A ligand lipophilicity (LLE) plot showing the
effects of changes by region revealed no significant correlation between
cellular potency and cLogP (see the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.3c00426/suppl_file/ml3c00426_si_001.pdf">Supporting Information</ext-link> for further information). The <italic>in vitro</italic> activity (IC<sub>50</sub> = 0.12 &#x003bc;M) and favorable physicochemical
properties placed methylindazole <bold>16</bold> within lead-like
chemical space (<xref rid="tbl5" ref-type="other">Table <xref rid="tbl5" ref-type="other">5</xref></xref>). The lipophilicity (cLogP = 2.3), topological polar surface area
(TPSA = 86), and numbers of HBDs (2) and hydrogen bond acceptors (HBAs)
(4) were all within the desired property space associated with lead
assets.<sup><xref ref-type="bibr" rid="ref44">44</xref></sup> The intrinsic property forecast
index (iPFI), a metric proposed by Young and co-workers,<sup><xref ref-type="bibr" rid="ref45">45</xref></sup> is the sum of cLogP and the aromatic ring count,
which is a predictor of important considerations such as solubility
and off-target effects and should be kept &#x0003c;7. The iPFI of compound <bold>16</bold> is in the acceptable range, with a value of 5.3. Moreover,
compound <bold>16</bold> has a ligand efficiency of 0.33 and a ligand-lipophilic
efficiency of 4.7.</p><table-wrap id="tbl5" position="float"><label>Table 5</label><caption><title>Physicochemical Properties and <italic>In Vitro</italic> Pharmacokinetic Profile of Compound <bold>16</bold></title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml3c00426_0010" id="GRAPHIC-d14e826-autogenerated" position="float"/><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/></colgroup><tbody><tr><td style="border:none;" align="left">VCaP GRE2-luciferase
IC<sub>50</sub></td><td style="border:none;" align="left">0.12&#x000a0;&#x003bc;M</td></tr><tr><td style="border:none;" align="left">solubility</td><td style="border:none;" align="left">2.6&#x000a0;&#x003bc;M</td></tr><tr><td style="border:none;" align="left">Caco2 permeability
P<sub>app</sub> A2B (nm/s); P<sub>app</sub> B2A (nm/s)</td><td style="border:none;" align="left">331;&#x000a0;394</td></tr><tr><td style="border:none;" align="left">Caco2 efflux ratio</td><td style="border:none;" align="left">1.2</td></tr><tr><td style="border:none;" align="left">HLM CL<sub>int</sub> (&#x003bc;L&#x000a0;min<sup>&#x02013;1</sup>&#x000a0;mg<sup>&#x02013;1</sup>)</td><td style="border:none;" align="left">25.6</td></tr><tr><td style="border:none;" align="left">HLM <italic>t</italic><sub>1/2</sub> (min)</td><td style="border:none;" align="left">54</td></tr><tr><td style="border:none;" align="left">plasma
fraction unbound (mouse)</td><td style="border:none;" align="left">6.9%</td></tr><tr><td style="border:none;" align="left">CYP IC<sub>50</sub> (3A4; 2D6)</td><td style="border:none;" align="left">&#x0003e;25&#x000a0;&#x003bc;M</td></tr><tr><td style="border:none;" align="left">hERG IC<sub>50</sub></td><td style="border:none;" align="left">&#x0003e;10&#x000a0;&#x003bc;M</td></tr></tbody></table></table-wrap><p>Having demonstrated robust <italic>in vitro</italic> and physicochemical
properties, we next sought to further probe the pharmacology of emerging
lead compound <bold>16</bold>. To this end, AR-v splice variant activity
was determined through transfection of PC3 cells with an AR<sub>NTD&#x02013;DBD</sub> expression plasmid and a GRE2-luciferase reporter gene (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>).<sup><xref ref-type="bibr" rid="ref43">43</xref></sup> This construct retains the constitutively active NTD/DBD
core; however, it is insensitive to LBD antagonists such as enzalutamide.
Compound <bold>16</bold> shows 35% inhibition of AR-v activity at
10 &#x003bc;M, whereas enzalutamide is not active in this assay. In
addition to this, we evaluated hormone-dependent expression of prostate-specific
antigen (PSA) in VCaP cells (see the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.3c00426/suppl_file/ml3c00426_si_001.pdf">Supporting Information</ext-link>). This showed a similar level of inhibition (34%),
confirming pathway-relevant pharmacological effects.</p><fig id="fig3" position="float"><label>Figure 3</label><caption><p>Small-molecule inhibition
of androgen receptor transcriptional
activity of compound <bold>16</bold> and enzalutamide (enza.).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml3c00426_0003" id="gr3" position="float"/></fig><p>We next explored the potential developability of
this compound
as a potent AR inhibitor with an investigation of the <italic>in vitro</italic> pharmacokinetic properties of <bold>16</bold> (<xref rid="tbl5" ref-type="other">Table <xref rid="tbl5" ref-type="other">5</xref></xref>). Compound <bold>16</bold> exhibited
a moderate thermodynamic aqueous solubility of 2.6 &#x003bc;M and good
Caco2 cell permeability (apical to basolateral of 33.1 nm/s and basolateral
to apical of 39.4 nm/s), with an efflux ratio of 1.2. Furthermore,
compound <bold>16</bold> displayed promising intrinsic clearance (CL<sub>int</sub>) in human liver microsomes and a half-life of 54 min. The
plasma protein binding of <bold>16</bold> was determined and showed
a free fraction of 6.9%. The potential for drug&#x02013;drug interactions
was next investigated, and no inhibition of CYP450 was observed (with
both 34A and 2D6 isoforms), while no hERG channel inhibition was observed
via a Q-patch clamp assay.</p><p>Encouraged by the promising <italic>in vitro</italic> profile,
compound <bold>16</bold> was advanced, and a pharmacokinetic (PK)
profile was obtained in male CD-1 mice (<xref rid="tbl6" ref-type="other">Table <xref rid="tbl6" ref-type="other">6</xref></xref>). When compound <bold>16</bold> was administered
intravenously (iv) at 1 mg/kg, a short half-life (<italic>t</italic><sub>1/2</sub>) of 0.29 h was observed along with a high clearance
of 126 mL min<sup>&#x02013;1</sup> kg<sup>&#x02013;1</sup>. The maximum
plasma concentration (<italic>C</italic><sub>max</sub>) was 432 ng/mL,
while the area under the curve (AUC) was 131 h&#x000b7;ng/mL (as can
be seen in the <italic>C</italic><sub>max</sub> versus time profile
in <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>). Following
an oral dose (p.o) of compound <bold>16</bold> at 10 mg/kg, a mean
half-life of 4 h was observed along with adequate plasma exposure
(<italic>C</italic><sub>max</sub> = 195 ng/mL) and measurable exposure
(AUC = 173 h&#x000b7;ng/mL) with an oral bioavailability (<italic>F</italic>) of 16%, suggesting that target engagement may be difficult to achieve
when considering the potency and exposure data.</p><table-wrap id="tbl6" position="float"><label>Table 6</label><caption><title><italic>In Vivo</italic> PK Profile
of Compound <bold>16</bold> in Mouse (<italic>n</italic> = 3)</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">PK parameters</th><th style="border:none;" align="center">iv&#x000a0;(1&#x000a0;mg/kg)</th><th style="border:none;" align="center">po&#x000a0;(10&#x000a0;mg/kg)</th></tr></thead><tbody><tr><td style="border:none;" align="left"><italic>t</italic><sub>1/2</sub> (h)</td><td style="border:none;" align="left">0.29</td><td style="border:none;" align="left">4</td></tr><tr><td style="border:none;" align="left"><italic>T</italic><sub>max</sub></td><td style="border:none;" align="left">n/a</td><td style="border:none;" align="left">0.25</td></tr><tr><td style="border:none;" align="left">CL (mL&#x000a0;min<sup>&#x02013;1</sup>&#x000a0;kg<sup>&#x02013;1</sup>)</td><td style="border:none;" align="left">126</td><td style="border:none;" align="left">n/a</td></tr><tr><td style="border:none;" align="left"><italic>C</italic><sub>max</sub> (ng/mL)</td><td style="border:none;" align="left">432</td><td style="border:none;" align="left">195</td></tr><tr><td style="border:none;" align="left">AUC<sub>0&#x02013;<italic>t</italic></sub> (h&#x000b7;ng/mL)</td><td style="border:none;" align="left">131</td><td style="border:none;" align="left">173</td></tr><tr><td style="border:none;" align="left">AUC<sub>0&#x02013;&#x0221e;</sub> (h&#x000b7;ng/mL)</td><td style="border:none;" align="left">132</td><td style="border:none;" align="left">208</td></tr><tr><td style="border:none;" align="left"><italic>V</italic><sub>ss_obs</sub> (L/kg)</td><td style="border:none;" align="left">1.38</td><td style="border:none;" align="left">n/a</td></tr><tr><td style="border:none;" align="left"><italic>F</italic> (%)</td><td style="border:none;" align="left">n/a</td><td style="border:none;" align="left">16</td></tr></tbody></table></table-wrap><fig id="fig4" position="float"><label>Figure 4</label><caption><p><italic>C</italic><sub>max</sub> versus time profile for compound <bold>16</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml3c00426_0011" id="gr4" position="float"/></fig><p>In summary, after identification and validation
of initial hit <bold>7</bold> as a weak binder of the AR NTD, 50 analogues
were synthesized
to explore the SAR and optimize potency. Investigations into region
1 revealed that several benzannulated N-heterocycles were tolerated
and had elevated activity compared to the initial hit. In particular,
the <italic>N</italic>-methylindazole analogue <bold>16</bold> showed
a 60-fold increase in potency over the progenitor compound <bold>7</bold>. Furthermore, compound <bold>16</bold> compared favorably in terms
of potency to the clinically deployed AR antagonist enzalutamide (IC<sub>50</sub> = 0.34 &#x003bc;M) and was more potent than known AR-NTD AF1
binder EPI-001 (IC<sub>50</sub> = 37.4 &#x003bc;M) under the assay conditions.
Together, the excellent potency, favorable physicochemical properties,
and benchmarked pharmacokinetic profile offer a starting point for
the further optimization of compound <bold>16</bold> as a tool compound
to investigate the pharmacology and engagement of the AR NTD. Further
optimization of this emerging chemical equity is underway in our laboratories,
focusing on tuning the metabolic profile to attain exposure consistent
with target engagement as well as biophysical studies of the interaction
with the AR-NTD, and will be reported in due course.</p></body><back><notes id="notes1" notes-type="si"><title>Supporting Information Available</title><p>The Supporting Information is
available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acsmedchemlett.3c00426?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsmedchemlett.3c00426</ext-link>.<list id="silist" list-type="simple"><list-item><p>Preparative details of all compounds and requisite intermediates,
associated spectral data, and bioassay procedures (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.3c00426/suppl_file/ml3c00426_si_001.pdf">PDF</ext-link>)</p></list-item></list></p></notes><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sifile1"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml3c00426_si_001.pdf"><caption><p>ml3c00426_si_001.pdf</p></caption></media></supplementary-material></sec><notes notes-type="" id="notes3"><title>Author Contributions</title><p><sup>&#x02225;</sup> M.C.H. and C.M.R. contributed equally. All
of the authors approved
the final version of the manuscript.</p></notes><notes notes-type="funding-statement" id="notes4"><p>We thank the
Medical Research Council (MR/T02559/X), Prostate Cancer Research (IH),
and GlaxoSmithKline for financial support of this work.</p></notes><notes notes-type="COI-statement" id="notes5"><p>The authors
declare no competing financial interest.</p></notes><ack><title>Acknowledgments</title><p>We thank Craig Irving for his assistance with NMR
spectroscopy and Pat Keating, Dr. Jessica Bame, and Dr. Graeme Anderson
for their assistance with HRMS.</p></ack><glossary id="dl1"><def-list><title>Abbreviations</title><def-item><term>ADT</term><def><p>androgen
depravation therapy</p></def></def-item><def-item><term>AF-1</term><def><p>activation function-1</p></def></def-item><def-item><term>AR</term><def><p>androgen receptor</p></def></def-item><def-item><term>AUC</term><def><p>area under the
curve</p></def></def-item><def-item><term>Cl<sub>int</sub></term><def><p>intrinsic clearance</p></def></def-item><def-item><term>CRPC</term><def><p>castration-resistant prostate cancer</p></def></def-item><def-item><term>CYP</term><def><p>cytochrome P</p></def></def-item><def-item><term>DBD</term><def><p>DNA binding domain</p></def></def-item><def-item><term>HBA</term><def><p>hydrogen-bond acceptor</p></def></def-item><def-item><term>HBD</term><def><p>hydrogen-bond donor</p></def></def-item><def-item><term>LBD</term><def><p>ligand binding
domain</p></def></def-item><def-item><term>LBP</term><def><p>ligand
binding pocket</p></def></def-item><def-item><term>NSAA</term><def><p>nonsteroidal anti-androgen</p></def></def-item><def-item><term>NTD</term><def><p>N-terminal domain</p></def></def-item><def-item><term>iPFI</term><def><p>intrinsic property forecast index</p></def></def-item><def-item><term>SAR</term><def><p>structure&#x02013;activity relationship</p></def></def-item><def-item><term>TPSA</term><def><p>topological polar surface
area.</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="weblink"><source>Global Cancer
Observatory</source>. <publisher-name>World Health Organization</publisher-name>, <year>2020</year>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://gco.iarc.fr/">https://gco.iarc.fr/</uri>.</mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="book" id="cit2"><source>Drug
Management of Prostate Cancer</source>; <person-group person-group-type="editor"><name><surname>Figg</surname><given-names>W. D.</given-names></name>, <name><surname>Chau</surname><given-names>C. H.</given-names></name>, <name><surname>Small</surname><given-names>E. J.</given-names></name></person-group>, Eds.; <publisher-name>Springer</publisher-name>, <year>2010</year></mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal" id="cit3"><name><surname>Imamura</surname><given-names>Y.</given-names></name>; <name><surname>Sadar</surname><given-names>M. D.</given-names></name>
<article-title>Androgen Receptor
Targeted Therapies in Castration-resistant
Prostate Cancer: Bench to Clinic</article-title>. <source>Int. J. Urol.</source>
<year>2016</year>, <volume>23</volume>, <fpage>654</fpage>&#x02013;<lpage>665</lpage>. <pub-id pub-id-type="doi">10.1111/iju.13137</pub-id>.<pub-id pub-id-type="pmid">27302572</pub-id>
</mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name><surname>Siegel</surname><given-names>R. L.</given-names></name>; <name><surname>Miller</surname><given-names>K. D.</given-names></name>; <name><surname>Jemal</surname><given-names>A.</given-names></name>
<article-title>Cancer statistics</article-title>. <source>CA Cancer J. Clin.</source>
<year>2019</year>, <volume>69</volume>, <fpage>7</fpage>&#x02013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.3322/caac.21551</pub-id>.<pub-id pub-id-type="pmid">30620402</pub-id>
</mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name><surname>Pienta</surname><given-names>K. J.</given-names></name>; <name><surname>Bradley</surname><given-names>D.</given-names></name>
<article-title>Mechanisms underlying the development of androgen-independent
prostate cancer</article-title>. <source>Clin. Cancer. Res.</source>
<year>2006</year>, <volume>12</volume>, <fpage>1665</fpage>&#x02013;<lpage>1671</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-0067</pub-id>.<pub-id pub-id-type="pmid">16551847</pub-id>
</mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name><surname>Harris</surname><given-names>W. P.</given-names></name>; <name><surname>Mostaghel</surname><given-names>E. A.</given-names></name>; <name><surname>Nelson</surname><given-names>P. S.</given-names></name>; <name><surname>Montgomery</surname><given-names>B.</given-names></name>
<article-title>Androgen Deprivation
Therapy: Progress in Understanding Mechanisms of Resistance and Optimizing
Androgen Depletion</article-title>. <source>Nat. Clin. Pract. Urol.</source>
<year>2009</year>, <volume>6</volume>, <fpage>76</fpage>&#x02013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1038/ncpuro1296</pub-id>.<pub-id pub-id-type="pmid">19198621</pub-id>
</mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><name><surname>Tan</surname><given-names>M. H. E.</given-names></name>; <name><surname>Li</surname><given-names>J.</given-names></name>; <name><surname>Xu</surname><given-names>H. E.</given-names></name>; <name><surname>Melcher</surname><given-names>K.</given-names></name>; <name><surname>Yong</surname><given-names>E.-L.</given-names></name>
<article-title>Androgen
receptor: structure, role in prostate cancer and drug discovery</article-title>. <source>Acta Pharmacol. Sin.</source>
<year>2015</year>, <volume>36</volume>, <fpage>3</fpage>&#x02013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1038/aps.2014.18</pub-id>.<pub-id pub-id-type="pmid">24909511</pub-id>
</mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name><surname>Helsen</surname><given-names>C.</given-names></name>; <name><surname>Van den Broeck</surname><given-names>T.</given-names></name>; <name><surname>Voet</surname><given-names>A.</given-names></name>; <name><surname>Prekovic</surname><given-names>S.</given-names></name>; <name><surname>Van Poppel</surname><given-names>H.</given-names></name>; <name><surname>Joniau</surname><given-names>S.</given-names></name>; <name><surname>Claessens</surname><given-names>F.</given-names></name>
<article-title>Androgen receptor antagonists for
prostate cancer therapy</article-title>. <source>Endocr. Relat. Cancer.</source>
<year>2014</year>, <volume>21</volume>, <fpage>T105</fpage>&#x02013;<lpage>T118</lpage>. <pub-id pub-id-type="doi">10.1530/ERC-13-0545</pub-id>.<pub-id pub-id-type="pmid">24639562</pub-id>
</mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name><surname>Crawford</surname><given-names>E. D.</given-names></name>; <name><surname>Schellhammer</surname><given-names>P. F.</given-names></name>; <name><surname>McLeod</surname><given-names>D. G.</given-names></name>; <name><surname>Moul</surname><given-names>J. W.</given-names></name>; <name><surname>Higano</surname><given-names>C. S.</given-names></name>; <name><surname>Shore</surname><given-names>N.</given-names></name>; <name><surname>Denis</surname><given-names>L.</given-names></name>; <name><surname>Iversen</surname><given-names>P.</given-names></name>; <name><surname>Eisenberger</surname><given-names>M. A.</given-names></name>; <name><surname>Labrie</surname><given-names>F.</given-names></name>
<article-title>Androgen Receptor Targeted Treatments of Prostate Cancer:
35 Years of Progress with Antiandrogens</article-title>. <source>J.
Urol.</source>
<year>2018</year>, <volume>200</volume>, <fpage>956</fpage>&#x02013;<lpage>966</lpage>. <pub-id pub-id-type="doi">10.1016/j.juro.2018.04.083</pub-id>.<pub-id pub-id-type="pmid">29730201</pub-id>
</mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name><surname>Est&#x000e9;banez-Perpi&#x000f1;&#x000e1;</surname><given-names>E.</given-names></name>; <name><surname>Bevan</surname><given-names>C. L.</given-names></name>; <name><surname>McEwan</surname><given-names>I. J.</given-names></name>
<article-title>Eighty Years of Targeting Androgen
Receptor Activity in Prostate Cancer: The Fight Goes on</article-title>. <source>Cancers</source>
<year>2021</year>, <volume>13</volume>, <fpage>509</fpage><pub-id pub-id-type="doi">10.3390/cancers13030509</pub-id>.<pub-id pub-id-type="pmid">33572755</pub-id>
</mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name><surname>Tran</surname><given-names>C.</given-names></name>; <name><surname>Ouk</surname><given-names>S.</given-names></name>; <name><surname>Clegg</surname><given-names>N. J.</given-names></name>; <name><surname>Chen</surname><given-names>Y.</given-names></name>; <name><surname>Watson</surname><given-names>P. A.</given-names></name>; <name><surname>Arora</surname><given-names>V.</given-names></name>; <name><surname>Wongvipat</surname><given-names>J.</given-names></name>; <name><surname>Smith-Jones</surname><given-names>P. M.</given-names></name>; <name><surname>Yoo</surname><given-names>D.</given-names></name>; <name><surname>Kwon</surname><given-names>A.</given-names></name>; <name><surname>Wasielewska</surname><given-names>T.</given-names></name>; <name><surname>Welsbie</surname><given-names>D.</given-names></name>; <name><surname>Chen</surname><given-names>C. D.</given-names></name>; <name><surname>Higano</surname><given-names>C. S.</given-names></name>; <name><surname>Beer</surname><given-names>T. M.</given-names></name>; <name><surname>Hung</surname><given-names>D. T.</given-names></name>; <name><surname>Scher</surname><given-names>H. I.</given-names></name>; <name><surname>Jung</surname><given-names>M. E.</given-names></name>; <name><surname>Sawyers</surname><given-names>C. L.</given-names></name>
<article-title>Development
of a Second Generation Antiandrogen for
Treatment of Advanced Prostate Cancer</article-title>. <source>Science</source>
<year>2009</year>, <volume>324</volume>, <fpage>787</fpage>&#x02013;<lpage>790</lpage>. <pub-id pub-id-type="doi">10.1126/science.1168175</pub-id>.<pub-id pub-id-type="pmid">19359544</pub-id>
</mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name><surname>Dellis</surname><given-names>A. E.</given-names></name>; <name><surname>Papatsoris</surname><given-names>A. G.</given-names></name>
<article-title>Apalutamide:
The Established and Emerging Roles in
the Treatment of Advanced Prostate Cancer</article-title>. <source>Expert
Opin. Invest. Drugs.</source>
<year>2018</year>, <volume>27</volume>, <fpage>553</fpage>&#x02013;<lpage>559</lpage>. <pub-id pub-id-type="doi">10.1080/13543784.2018.1484107</pub-id>.</mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name><surname>Moilanen</surname><given-names>A.-M.</given-names></name>; <name><surname>Riikonen</surname><given-names>R.</given-names></name>; <name><surname>Oksala</surname><given-names>R.</given-names></name>; <name><surname>Ravanti</surname><given-names>L.</given-names></name>; <name><surname>Aho</surname><given-names>E.</given-names></name>; <name><surname>Wohlfahrt</surname><given-names>G.</given-names></name>; <name><surname>Nyk&#x000e4;nen</surname><given-names>P. S.</given-names></name>; <name><surname>T&#x000f6;rm&#x000e4;kangas</surname><given-names>O. P.</given-names></name>; <name><surname>Palvimo</surname><given-names>J. J.</given-names></name>; <name><surname>Kallio</surname><given-names>P. J.</given-names></name>
<article-title>Discovery of ODM-201, A New-Generation
Androgen Receptor Inhibitor Targeting Resistance Mechanisms to Androgen
Signalling-Directed Prostate Cancer Therapies</article-title>. <source>Sci. Rep.</source>
<year>2015</year>, <volume>5</volume>, <fpage>12007</fpage><pub-id pub-id-type="doi">10.1038/srep12007</pub-id>.<pub-id pub-id-type="pmid">26137992</pub-id>
</mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name><surname>Chandrasekar</surname><given-names>T.</given-names></name>; <name><surname>Yang</surname><given-names>J. C.</given-names></name>; <name><surname>Gao</surname><given-names>A. C.</given-names></name>; <name><surname>Evans</surname><given-names>C. P.</given-names></name>
<article-title>Mechanisms of resistance
in castration-resistant prostate cancer (CRPC)</article-title>. <source>Transl. Androl. Urol.</source>
<year>2015</year>, <volume>4</volume>, <fpage>365</fpage>&#x02013;<lpage>380</lpage>. <pub-id pub-id-type="doi">10.3978/j.issn.2223-4683.2015.05.02</pub-id>.<pub-id pub-id-type="pmid">26814148</pub-id>
</mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name><surname>Watson</surname><given-names>P. A.</given-names></name>; <name><surname>Arora</surname><given-names>V. K.</given-names></name>; <name><surname>Sawyers</surname><given-names>C. L.</given-names></name>
<article-title>Emerging
mechanisms of resistance
to androgen receptor inhibitors in prostate cancer</article-title>. <source>Nat. Rev. Cancer</source>
<year>2015</year>, <volume>15</volume>, <fpage>701</fpage>&#x02013;<lpage>711</lpage>. <pub-id pub-id-type="doi">10.1038/nrc4016</pub-id>.<pub-id pub-id-type="pmid">26563462</pub-id>
</mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name><surname>Tilki</surname><given-names>D.</given-names></name>; <name><surname>Schaeffer</surname><given-names>E. M.</given-names></name>; <name><surname>Evans</surname><given-names>C. P.</given-names></name>
<article-title>Understanding Mechanisms of Resistance
in Metastatic Castration-resistant Prostate Cancer: The Role of the
Androgen Receptor</article-title>. <source>Eur. Urol. Focus</source>
<year>2016</year>, <volume>2</volume>, <fpage>499</fpage>&#x02013;<lpage>505</lpage>. <pub-id pub-id-type="doi">10.1016/j.euf.2016.11.013</pub-id>.<pub-id pub-id-type="pmid">28723515</pub-id>
</mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name><surname>Crona</surname><given-names>D. J.</given-names></name>; <name><surname>Whang</surname><given-names>Y. E.</given-names></name>
<article-title>Androgen Receptor-Dependent
and -Independent Mechanisms
Involved in Prostate Cancer Therapy Resistance</article-title>. <source>Cancers</source>
<year>2017</year>, <volume>9</volume>, <fpage>67</fpage><pub-id pub-id-type="doi">10.3390/cancers9060067</pub-id>.<pub-id pub-id-type="pmid">28604629</pub-id>
</mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><name><surname>Huang</surname><given-names>Y.</given-names></name>; <name><surname>Jiang</surname><given-names>X.</given-names></name>; <name><surname>Liang</surname><given-names>X.</given-names></name>; <name><surname>Jiang</surname><given-names>G.</given-names></name>
<article-title>Molecular and cellular
mechanisms of castration-resistant prostate cancer</article-title>. <source>Oncol. Lett.</source>
<year>2018</year>, <volume>15</volume>, <fpage>6063</fpage>&#x02013;<lpage>6076</lpage>. <pub-id pub-id-type="doi">10.3892/ol.2018.8123</pub-id>.<pub-id pub-id-type="pmid">29616091</pub-id>
</mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name><surname>Schmidt</surname><given-names>K. T.</given-names></name>; <name><surname>Huitema</surname><given-names>A. D. R.</given-names></name>; <name><surname>Chau</surname><given-names>C. H.</given-names></name>; <name><surname>Figg</surname><given-names>W. D.</given-names></name>
<article-title>Resistance to Second-Generation
Androgen Receptor Antagonists in Prostate Cancer</article-title>. <source>Nat. Rev. Urol.</source>
<year>2021</year>, <volume>18</volume>, <fpage>209</fpage>&#x02013;<lpage>226</lpage>. <pub-id pub-id-type="doi">10.1038/s41585-021-00438-4</pub-id>.<pub-id pub-id-type="pmid">33742189</pub-id>
</mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name><surname>Lallous</surname><given-names>N.</given-names></name>; <name><surname>Dalal</surname><given-names>K.</given-names></name>; <name><surname>Cherkasov</surname><given-names>A.</given-names></name>; <name><surname>Rennie</surname><given-names>P. S.</given-names></name>
<article-title>Targeting Alternative
Sites on the Androgen Receptor to Treat Castration-Resistant Prostate
Cancer</article-title>. <source>Int. J. Mol. Sci.</source>
<year>2013</year>, <volume>14</volume>, <fpage>12496</fpage>&#x02013;<lpage>12519</lpage>. <pub-id pub-id-type="doi">10.3390/ijms140612496</pub-id>.<pub-id pub-id-type="pmid">23771019</pub-id>
</mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal" id="cit21"><name><surname>Elshan</surname><given-names>N. G. R. D.</given-names></name>; <name><surname>Rettig</surname><given-names>M. B.</given-names></name>; <name><surname>Jung</surname><given-names>M. E.</given-names></name>
<article-title>Molecules
targeting the androgen
receptor (AR) signalling axis beyond the AR-Ligand binding domain</article-title>. <source>Med. Res. Rev.</source>
<year>2019</year>, <volume>39</volume>, <fpage>910</fpage>&#x02013;<lpage>960</lpage>. <pub-id pub-id-type="doi">10.1002/med.21548</pub-id>.<pub-id pub-id-type="pmid">30565725</pub-id>
</mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name><surname>Riley</surname><given-names>C. M.</given-names></name>; <name><surname>Elwood</surname><given-names>J. M. L.</given-names></name>; <name><surname>Henry</surname><given-names>M. C.</given-names></name>; <name><surname>Hunter</surname><given-names>I.</given-names></name>; <name><surname>Lopez-Fernandez</surname><given-names>J. D.</given-names></name>; <name><surname>McEwan</surname><given-names>I. J.</given-names></name>; <name><surname>Jamieson</surname><given-names>C.</given-names></name>
<article-title>Current and Emerging Approaches to
Noncompetitive AR inhibition</article-title>. <source>Med. Res. Rev.</source>
<year>2023</year>, <volume>43</volume>, <fpage>1701</fpage><pub-id pub-id-type="doi">10.1002/med.21961</pub-id>.<pub-id pub-id-type="pmid">37062876</pub-id>
</mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal" id="cit23"><name><surname>Jenster</surname><given-names>G.</given-names></name>; <name><surname>Van der Korput</surname><given-names>H. A.</given-names></name>; <name><surname>Trapman</surname><given-names>J.</given-names></name>; <name><surname>Brinkmann</surname><given-names>A. O.</given-names></name>
<article-title>Identification
of Two Transcription Activation Units in the <italic>N</italic>-Terminal
Domain of the Human Androgen Receptor</article-title>. <source>J. Biol.
Chem.</source>
<year>1995</year>, <volume>270</volume>, <fpage>7341</fpage>&#x02013;<lpage>7346</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.270.13.7341</pub-id>.<pub-id pub-id-type="pmid">7706276</pub-id>
</mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal" id="cit24"><name><surname>Reid</surname><given-names>J.</given-names></name>; <name><surname>Kelly</surname><given-names>S. M.</given-names></name>; <name><surname>Watt</surname><given-names>K.</given-names></name>; <name><surname>Price</surname><given-names>N. C.</given-names></name>; <name><surname>McEwan</surname><given-names>I. J.</given-names></name>
<article-title>Conformational
Analysis of the Androgen Receptor Amino-Terminal Domain Involved in
Transactivation. Influence of Structure-Stabilizing Solutes and Protein-Protein
Interactions</article-title>. <source>J. Biol. Chem.</source>
<year>2002</year>, <volume>277</volume>, <fpage>20079</fpage>&#x02013;<lpage>20086</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M201003200</pub-id>.<pub-id pub-id-type="pmid">11896058</pub-id>
</mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal" id="cit25"><name><surname>McEwan</surname><given-names>I. J.</given-names></name>
<article-title>Intrinsic
Disorder in the Androgen Receptor: Identification, Characterisation
and Drugability</article-title>. <source>Mol. BioSyst.</source>
<year>2012</year>, <volume>8</volume>, <fpage>82</fpage>&#x02013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1039/C1MB05249G</pub-id>.<pub-id pub-id-type="pmid">21822504</pub-id>
</mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal" id="cit26"><name><surname>Monaghan</surname><given-names>A.</given-names></name>; <name><surname>McEwan</surname><given-names>I.</given-names></name>
<article-title>A Sting in the Tail:
the <italic>N</italic>-Terminal
Domain of the Androgen Receptor as a Drug Target</article-title>. <source>Asian J. Androl.</source>
<year>2016</year>, <volume>18</volume>, <fpage>687</fpage>&#x02013;<lpage>694</lpage>. <pub-id pub-id-type="doi">10.4103/1008-682X.181081</pub-id>.<pub-id pub-id-type="pmid">27212126</pub-id>
</mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal" id="cit27"><name><surname>Antonarakis</surname><given-names>E. S.</given-names></name>; <name><surname>Chandhasin</surname><given-names>C.</given-names></name>; <name><surname>Osbourne</surname><given-names>E.</given-names></name>; <name><surname>Luo</surname><given-names>J.</given-names></name>; <name><surname>Sadar</surname><given-names>M. D.</given-names></name>; <name><surname>Perabo</surname><given-names>F.</given-names></name>
<article-title>Targeting the <italic>N</italic>-Terminal
Domain of
the Androgen Receptor: A New Approach for the Treatment of Advanced
Prostate Cancer</article-title>. <source>Oncologist</source>
<year>2016</year>, <volume>21</volume>, <fpage>1427</fpage>&#x02013;<lpage>1435</lpage>. <pub-id pub-id-type="doi">10.1634/theoncologist.2016-0161</pub-id>.<pub-id pub-id-type="pmid">27628492</pub-id>
</mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal" id="cit28"><name><surname>Hupe</surname><given-names>M. C.</given-names></name>; <name><surname>Offermann</surname><given-names>A.</given-names></name>; <name><surname>Perabo</surname><given-names>F.</given-names></name>; <name><surname>Chandhasin</surname><given-names>C.</given-names></name>; <name><surname>Perner</surname><given-names>S.</given-names></name>; <name><surname>Merseburger</surname><given-names>A. S.</given-names></name>; <name><surname>Cronauer</surname><given-names>M. V.</given-names></name>
<article-title>Inhibitors of the
Androgen Receptor <italic>N</italic>-Terminal Domain: Therapies Targeting
the Achilles&#x02019; Heel of Various Androgen Receptor Molecules in
Advanced Prostate Cancer</article-title>. <source>Urologe</source>
<year>2018</year>, <volume>57</volume>, <fpage>148</fpage>&#x02013;<lpage>154</lpage>. <pub-id pub-id-type="doi">10.1007/s00120-017-0541-y</pub-id>.</mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal" id="cit29"><name><surname>Sadar</surname><given-names>M. D.</given-names></name>
<article-title>Discovery
of Drugs that Directly Target the Intrinsically Disordered Region
of the Androgen Receptor</article-title>. <source>Expert Opin. Drug
Discovery</source>
<year>2020</year>, <volume>15</volume>, <fpage>551</fpage>&#x02013;<lpage>560</lpage>. <pub-id pub-id-type="doi">10.1080/17460441.2020.1732920</pub-id>.</mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal" id="cit30"><name><surname>Ji</surname><given-names>Y.</given-names></name>; <name><surname>Zhang</surname><given-names>R.</given-names></name>; <name><surname>Han</surname><given-names>X.</given-names></name>; <name><surname>Zhou</surname><given-names>J.</given-names></name>
<article-title>Targeting the <italic>N</italic>-Terminal Domain of
the Androgen Receptor: The Effective
Approach in Therapy of CRPC</article-title>. <source>Eur. J. Med. Chem.</source>
<year>2023</year>, <volume>247</volume>, <fpage>115077</fpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2022.115077</pub-id>.<pub-id pub-id-type="pmid">36587421</pub-id>
</mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal" id="cit31"><name><surname>Li</surname><given-names>H.</given-names></name>; <name><surname>Hassona</surname><given-names>M. D. H.</given-names></name>; <name><surname>Lack</surname><given-names>N. A.</given-names></name>; <name><surname>Axerio-Cilies</surname><given-names>P.</given-names></name>; <name><surname>Leblanc</surname><given-names>E.</given-names></name>; <name><surname>Tavassoli</surname><given-names>P.</given-names></name>; <name><surname>Kanaan</surname><given-names>N.</given-names></name>; <name><surname>Frewin</surname><given-names>K.</given-names></name>; <name><surname>Singh</surname><given-names>K.</given-names></name>; <name><surname>Adomat</surname><given-names>H.</given-names></name>; <name><surname>B&#x000f6;hm</surname><given-names>K. J.</given-names></name>; <name><surname>Prinz</surname><given-names>H.</given-names></name>; <name><surname>Guns</surname><given-names>E. T.</given-names></name>; <name><surname>Rennie</surname><given-names>P. S.</given-names></name>; <name><surname>Cherkasov</surname><given-names>A.</given-names></name>
<article-title>Characterization
of a New Class of Androgen Receptor Antagonists with Potential Therapeutic
Application in Advanced Prostate Cancer</article-title>. <source>Mol.
Cancer Ther.</source>
<year>2013</year>, <volume>12</volume>, <fpage>2425</fpage>&#x02013;<lpage>2435</lpage>. <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-13-0267</pub-id>.<pub-id pub-id-type="pmid">23939374</pub-id>
</mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal" id="cit32"><name><surname>Banuelos</surname><given-names>C. A.</given-names></name>; <name><surname>Lal</surname><given-names>A.</given-names></name>; <name><surname>Tien</surname><given-names>A. H.</given-names></name>; <name><surname>Shah</surname><given-names>N.</given-names></name>; <name><surname>Yang</surname><given-names>Y. C.</given-names></name>; <name><surname>Mawji</surname><given-names>N. R.</given-names></name>; <name><surname>Meimetis</surname><given-names>L. G.</given-names></name>; <name><surname>Park</surname><given-names>J.</given-names></name>; <name><surname>Kunzhong</surname><given-names>J.</given-names></name>; <name><surname>Andersen</surname><given-names>R. J.</given-names></name>; <name><surname>Sadar</surname><given-names>M. D.</given-names></name>
<article-title>Characterisation of Niphatenones that Inhibit Androgen
Receptor <italic>N</italic>-Terminal Domain</article-title>. <source>PLoS One</source>
<year>2014</year>, <volume>9</volume>, <elocation-id>e107991</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0107991</pub-id>.<pub-id pub-id-type="pmid">25268119</pub-id>
</mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal" id="cit33"><name><surname>Banuelos</surname><given-names>C. A.</given-names></name>; <name><surname>Tavakoli</surname><given-names>I.</given-names></name>; <name><surname>Tien</surname><given-names>A. H.</given-names></name>; <name><surname>Caley</surname><given-names>D. P.</given-names></name>; <name><surname>Mawji</surname><given-names>N. R.</given-names></name>; <name><surname>Li</surname><given-names>Z.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Yang</surname><given-names>Y. C.</given-names></name>; <name><surname>Imamura</surname><given-names>Y.</given-names></name>; <name><surname>Yan</surname><given-names>L.</given-names></name>; <name><surname>Wen</surname><given-names>J. G.</given-names></name>; <name><surname>Andersen</surname><given-names>R. J.</given-names></name>; <name><surname>Sadar</surname><given-names>M. D.</given-names></name>
<article-title>Sintokamide A is
a Novel Antagonist of Androgen Receptor that Uniquely Binds Activation
Function-1 in its Amino-terminal Domain</article-title>. <source>J.
Biol. Chem.</source>
<year>2016</year>, <volume>291</volume>, <fpage>22231</fpage>&#x02013;<lpage>22243</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M116.734475</pub-id>.<pub-id pub-id-type="pmid">27576691</pub-id>
</mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal" id="cit34"><name><surname>Peng</surname><given-names>S.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Chen</surname><given-names>H.</given-names></name>; <name><surname>Hu</surname><given-names>P.</given-names></name>; <name><surname>He</surname><given-names>X.-L.</given-names></name>; <name><surname>He</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>M.</given-names></name>; <name><surname>Tang</surname><given-names>W.</given-names></name>; <name><surname>He</surname><given-names>Q.</given-names></name>; <name><surname>Wang</surname><given-names>Y.-Y.</given-names></name>; <name><surname>Xie</surname><given-names>J.</given-names></name>; <name><surname>Guo</surname><given-names>D.</given-names></name>; <name><surname>Ren</surname><given-names>S.</given-names></name>; <name><surname>Liu</surname><given-names>M.</given-names></name>; <name><surname>Qiu</surname><given-names>W.-W.</given-names></name>; <name><surname>Yi</surname><given-names>Z.</given-names></name>
<article-title>Regression of Castration-Resistant Prostate Cancer by a Novel Compound
QW07 Targeting Androgen Receptor <italic>N</italic>-Terminal Domain</article-title>. <source>Cell. Biol. Toxicol.</source>
<year>2020</year>, <volume>36</volume>, <fpage>399</fpage>&#x02013;<lpage>416</lpage>. <pub-id pub-id-type="doi">10.1007/s10565-020-09511-x</pub-id>.<pub-id pub-id-type="pmid">32002708</pub-id>
</mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal" id="cit35"><name><surname>Yang</surname><given-names>Z.</given-names></name>; <name><surname>Wang</surname><given-names>D.</given-names></name>; <name><surname>Johnson</surname><given-names>J. K.</given-names></name>; <name><surname>Pascal</surname><given-names>L. E.</given-names></name>; <name><surname>Takubo</surname><given-names>K.</given-names></name>; <name><surname>Avula</surname><given-names>R.</given-names></name>; <name><surname>Chakka</surname><given-names>A. B.</given-names></name>; <name><surname>Zhou</surname><given-names>J.</given-names></name>; <name><surname>Chen</surname><given-names>W.</given-names></name>; <name><surname>Zhong</surname><given-names>M.</given-names></name>; <name><surname>Song</surname><given-names>Q.</given-names></name>; <name><surname>Ding</surname><given-names>H.</given-names></name>; <name><surname>Wu</surname><given-names>Z.</given-names></name>; <name><surname>Chandran</surname><given-names>U. R.</given-names></name>; <name><surname>Maskrey</surname><given-names>T. S.</given-names></name>; <name><surname>Nelson</surname><given-names>J. B.</given-names></name>; <name><surname>Wipf</surname><given-names>P.</given-names></name>; <name><surname>Wang</surname><given-names>Z.</given-names></name>
<article-title>A Novel Small Molecule Targets Androgen Receptor and Its Splice Variants
in Castration-Resistant Prostate Cancer</article-title>. <source>Mol.
Cancer Ther.</source>
<year>2020</year>, <volume>19</volume>, <fpage>75</fpage>&#x02013;<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-19-0489</pub-id>.<pub-id pub-id-type="pmid">31554654</pub-id>
</mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal" id="cit36"><name><surname>Andersen</surname><given-names>R. J.</given-names></name>; <name><surname>Mawji</surname><given-names>N. R.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Wang</surname><given-names>G.</given-names></name>; <name><surname>Haile</surname><given-names>S.</given-names></name>; <name><surname>Myung</surname><given-names>J.-K.</given-names></name>; <name><surname>Watt</surname><given-names>K.</given-names></name>; <name><surname>Tam</surname><given-names>T.</given-names></name>; <name><surname>Yang</surname><given-names>Y.-C.</given-names></name>; <name><surname>Ba&#x000f1;uelos</surname><given-names>C. A.</given-names></name>; <name><surname>Williams</surname><given-names>D. E.</given-names></name>; <name><surname>McEwan</surname><given-names>I. J.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Sadar</surname><given-names>M. D.</given-names></name>
<article-title>Regression of Castrate-Recurrent Prostate Cancer by
a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen
Receptor</article-title>. <source>Cancer Cell</source>
<year>2010</year>, <volume>17</volume>, <fpage>535</fpage>&#x02013;<lpage>546</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccr.2010.04.027</pub-id>.<pub-id pub-id-type="pmid">20541699</pub-id>
</mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal" id="cit37"><name><surname>Myung</surname><given-names>J.-K.</given-names></name>; <name><surname>Ba&#x000f1;uelos</surname><given-names>C. A.</given-names></name>; <name><surname>Fernandez</surname><given-names>J. G.</given-names></name>; <name><surname>Mawji</surname><given-names>N. R.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Tien</surname><given-names>A. H.</given-names></name>; <name><surname>Yang</surname><given-names>Y. C.</given-names></name>; <name><surname>Tavakoli</surname><given-names>I.</given-names></name>; <name><surname>Haile</surname><given-names>S.</given-names></name>; <name><surname>Watt</surname><given-names>K.</given-names></name>; <name><surname>McEwan</surname><given-names>I. J.</given-names></name>; <name><surname>Plymate</surname><given-names>S.</given-names></name>; <name><surname>Andersen</surname><given-names>R. J.</given-names></name>; <name><surname>Sadar</surname><given-names>M. D.</given-names></name>
<article-title>An Androgen
Receptor N-Terminal Domain Antagonist for
Treating Prostate Cancer</article-title>. <source>J. Clin. Invest.</source>
<year>2013</year>, <volume>123</volume>, <fpage>2948</fpage>&#x02013;<lpage>2960</lpage>. <pub-id pub-id-type="doi">10.1172/JCI66398</pub-id>.<pub-id pub-id-type="pmid">23722902</pub-id>
</mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal" id="cit38"><name><surname>Yang</surname><given-names>Y. C.</given-names></name>; <name><surname>Ba&#x000f1;uelos</surname><given-names>C. A.</given-names></name>; <name><surname>Mawji</surname><given-names>N. R.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Kato</surname><given-names>M.</given-names></name>; <name><surname>Haile</surname><given-names>S.</given-names></name>; <name><surname>McEwan</surname><given-names>I. J.</given-names></name>; <name><surname>Plymate</surname><given-names>S.</given-names></name>; <name><surname>Sadar</surname><given-names>M. D.</given-names></name>
<article-title>Targeting
Androgen Receptor Activation Function-1 with EPI to Overcome Resistance
Mechanisms in Castration-Resistant Prostate Cancer</article-title>. <source>Clin. Cancer Res.</source>
<year>2016</year>, <volume>22</volume>, <fpage>4466</fpage>&#x02013;<lpage>4477</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-2901</pub-id>.<pub-id pub-id-type="pmid">27140928</pub-id>
</mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal" id="cit39"><name><surname>De
Mol</surname><given-names>E.</given-names></name>; <name><surname>Fenwick</surname><given-names>R. B.</given-names></name>; <name><surname>Phang</surname><given-names>C. T. W.</given-names></name>; <name><surname>Buz&#x000f3;n</surname><given-names>V.</given-names></name>; <name><surname>Szulc</surname><given-names>E.</given-names></name>; <name><surname>de la Fuente</surname><given-names>A.</given-names></name>; <name><surname>Escobedo</surname><given-names>A.</given-names></name>; <name><surname>Garcia</surname><given-names>J.</given-names></name>; <name><surname>Bertoncini</surname><given-names>C. W.</given-names></name>; <name><surname>Est&#x000e9;banez-Perpi&#x000f1;&#x000e1;</surname><given-names>E.</given-names></name>; <name><surname>McEwan</surname><given-names>I. J.</given-names></name>; <name><surname>Riera</surname><given-names>A.</given-names></name>; <name><surname>Salvatella</surname><given-names>X.</given-names></name>
<article-title>EPI-001, A
Compound Active against Castration-Resistant Prostate Cancer, Targets
Transactivation Unit 5 of the Androgen Receptor</article-title>. <source>ACS Chem. Biol.</source>
<year>2016</year>, <volume>11</volume>, <fpage>2499</fpage>&#x02013;<lpage>2505</lpage>. <pub-id pub-id-type="doi">10.1021/acschembio.6b00182</pub-id>.<pub-id pub-id-type="pmid">27356095</pub-id>
</mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal" id="cit40"><name><surname>Zhu</surname><given-names>J.</given-names></name>; <name><surname>Salvatella</surname><given-names>X.</given-names></name>; <name><surname>Robustelli</surname><given-names>P.</given-names></name>
<article-title>Small Molecules Targeting the Disordered
Transactivation Domain of the Androgen Receptor Induce the Formation
of Collapsed Helical States</article-title>. <source>Nat. Commun.</source>
<year>2022</year>, <volume>13</volume>, <fpage>6390</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-34077-z</pub-id>.<pub-id pub-id-type="pmid">36302916</pub-id>
</mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal" id="cit41"><name><surname>Le
Moigne</surname><given-names>R.</given-names></name>; <name><surname>Ba&#x000f1;uelos</surname><given-names>C. A.</given-names></name>; <name><surname>Mawji</surname><given-names>N. R.</given-names></name>; <name><surname>Tam</surname><given-names>T.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Jian</surname><given-names>K.</given-names></name>; <name><surname>Andersen</surname><given-names>R. J.</given-names></name>; <name><surname>Cesano</surname><given-names>A.</given-names></name>; <name><surname>Sadar</surname><given-names>M. D.</given-names></name>; <name><surname>Zhou</surname><given-names>H.-J.</given-names></name>; <name><surname>Virsik</surname><given-names>P.</given-names></name>
<article-title>IND candidate EPI-7386
as an <italic>N</italic>-Terminal Domain Androgen Receptor Inhibitor
in Development for the Treatment of Prostate Cancer</article-title>. <source>J. Clin. Oncol.</source>
<year>2020</year>, <volume>38</volume>, <fpage>142</fpage><pub-id pub-id-type="doi">10.1200/JCO.2020.38.6_suppl.142</pub-id>.</mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal" id="cit42"><name><surname>Laccetti</surname><given-names>A. L.</given-names></name>; <name><surname>Chatta</surname><given-names>G. S.</given-names></name>; <name><surname>Iannotti</surname><given-names>N.</given-names></name>; <name><surname>Kyriakopoulos</surname><given-names>C.</given-names></name>; <name><surname>Villaluna</surname><given-names>K.</given-names></name>; <name><surname>Le Moigne</surname><given-names>R.</given-names></name>; <name><surname>Cesano</surname><given-names>A.</given-names></name>
<article-title>Phase1/2 Study of EPI-7386
in Combination with Enzalutamide (enz) Compared with enz Alone in
Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)</article-title>. <source>J. Clin. Oncol.</source>
<year>2023</year>, <volume>41</volume>, <fpage>179</fpage>&#x02013;<lpage>179</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2023.41.6_suppl.179</pub-id>.</mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal" id="cit43"><name><surname>Monaghan</surname><given-names>A. E.</given-names></name>; <name><surname>Porter</surname><given-names>A.</given-names></name>; <name><surname>Hunter</surname><given-names>I.</given-names></name>; <name><surname>Morrison</surname><given-names>A.</given-names></name>; <name><surname>McElroy</surname><given-names>S. P.</given-names></name>; <name><surname>McEwan</surname><given-names>I. J.</given-names></name>
<article-title>Development of a
High-Throughput Screening Assay for
Small-Molecule Inhibitors of Androgen Receptor Splice Variants</article-title>. <source>Assay Drug Dev. Technol.</source>
<year>2022</year>, <volume>20</volume>, <fpage>111</fpage>&#x02013;<lpage>124</lpage>. <pub-id pub-id-type="doi">10.1089/adt.2021.128</pub-id>.<pub-id pub-id-type="pmid">35333596</pub-id>
</mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal" id="cit44"><name><surname>Sander</surname><given-names>T.</given-names></name>; <name><surname>Freyss</surname><given-names>J.</given-names></name>; <name><surname>von Korff</surname><given-names>M.</given-names></name>; <name><surname>Rufener</surname><given-names>C.</given-names></name>
<article-title>DataWarrior: An Open-Source
Program for Chemistry Aware Data Visualization and Analysis</article-title>. <source>J. Chem. Inf. Model.</source>
<year>2015</year>, <volume>55</volume>, <fpage>460</fpage>&#x02013;<lpage>473</lpage>. <pub-id pub-id-type="doi">10.1021/ci500588j</pub-id>.<pub-id pub-id-type="pmid">25558886</pub-id>
</mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal" id="cit45"><name><surname>Young</surname><given-names>R. J.</given-names></name>; <name><surname>Green</surname><given-names>D. V. S.</given-names></name>; <name><surname>Luscombe</surname><given-names>C. N.</given-names></name>; <name><surname>Hill</surname><given-names>A. P.</given-names></name>
<article-title>Getting Physical
in Drug Discovery II: The Impact of Chromatographic Hydrophobicity
Measurements and Aromaticity</article-title>. <source>Drug Discovery
Today</source>
<year>2011</year>, <volume>16</volume>, <fpage>822</fpage>&#x02013;<lpage>830</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2011.06.001</pub-id>.<pub-id pub-id-type="pmid">21704184</pub-id>
</mixed-citation></ref></ref-list></back></article>
